Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin
- 8 January 2003
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 192 (2) , 227-235
- https://doi.org/10.1016/s0304-3835(02)00686-9
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancerInternational Journal of Cancer, 1997
- p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial overian carcinomaCancer, 1995
- Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinomaCancer, 1995
- Cancer statistics, 1995CA: A Cancer Journal for Clinicians, 1995
- Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.Journal of Clinical Oncology, 1995
- p53 Expression in Epithelial Ovarian Neoplasms: Relationship to Clinical and Pathological Parameters, Ki-67 Expression and Flow CytometryGynecologic Oncology, 1994
- Prognostic significance of p53 immunostaining in epithelial ovarian cancer.Journal of Clinical Oncology, 1994
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993
- p53 gene mutations and protein accumulation in human ovarian cancer.Proceedings of the National Academy of Sciences, 1993
- The p53 proto-oncogene can act as a suppressor of transformationCell, 1989